

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

HG-3

RRID:CVCL_Y547

Type: Cell Line

Proper Citation

RRID:CVCL_Y547

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_Y547

Proper Citation: RRID:CVCL_Y547

Description: Cell line HG-3 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Chronic lymphocytic leukemia

Defining Citation: [PMID:22720208](#), [PMID:23297799](#), [PMID:27566572](#), [PMID:28489572](#), [PMID:31160637](#)

Comments: Characteristics: Genetically heterogeneous, consists of 3 subclones (PubMed=27566572)., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: HG-3

Synonyms: HG3

Cross References: ArrayExpress:E-MTAB-4527, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, Cell_Model_Passport:SIDM01817, DepMap:ACH-001520, DSMZ:ACC-765, DSMZCellDive:ACC-765, Wikidata:Q54883310

ID: CVCL_Y547

Record Creation Time: 20220427T220341+0000

Record Last Update: 20260905T180303+0000

Ratings and Alerts

No rating or validation information has been found for HG-3.

No alerts have been found for HG-3.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhao S, et al. (2026) RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response. *Molecular cell*, 86(7), 1275.

Reversat A, et al. (2025) Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway. *European journal of immunology*, 55(12), e70101.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. *Cancer research communications*, 4(5), 1328.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Schleser SW, et al. (2023) Palladium and Platinum Complexes of the Antimetabolite Fludarabine with Vastly Enhanced Selectivity for Tumour over Non-Malignant Cells. *Molecules (Basel, Switzerland)*, 28(13).

Pan H, et al. (2021) Discovery of Candidate DNA Methylation Cancer Driver Genes. *Cancer discovery*, 11(9), 2266.

Ott CJ, et al. (2018) Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. *Cancer cell*, 34(6), 982.